Skip to main content

Market access for medical technologies in Italy

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Italy

dfghjk

Key topics

There are two key themes describing market access for medical technologies in Italy:

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement 
  • Health technology assessment: assessments by national and regional HTA organizations
     
ghj

Reimbursement

Reimbursement of hospital care in Italy depends on the “ownership” status of hospitals and includes diagnosis-related group (DRG) and global budget mechanisms. 

Reimbursement of the hospital activity is made solely through a diagnosis-related group (DRG) system. Italy does not have its own system and adopted the CMS DRG version 24. The system is very rigid at the national level, with no updates made since the adoption of the DRG system. 

DRGs are determined by the combination of a procedure code and a diagnosis code (ICD-9-CM from the 2007 year). Procedure codes have not been updated since 2007, and many innovative technologies cannot be appropriately coded in the Italian system.

Regions can establish their own tariffs and can innovate on the structure of the DRG system. This includes the creation of DRG sub-categories (DRG split mechanism) or add-on reimbursement for expensive procedures or devices. 

cvbn

Health technology assessment

HTAs are performed at the national level by AGENAS and in several regions. In early 2024, the National HTA Program for Medical Devices became fully functional with the initiation of the first evaluations of technologies.

1111

Specifics for IVD tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via the regional reimbursement catalogs (using an adaptation of ICD-9-CM classification) in outpatient settings.

MTRC has experience with more than 297 projects in Italy

News and insights

Italy Expands LEA Coverage for Screening, IVD Tests and Prosthetic Aids, with €149.5 Million in Additional Funding

On 30 September 2026, Italy published two decrees updating the national Essential Levels of Care (Livelli Essenziali di Assistenza, LEA). The changes combine an approximately €149.5 million expansion of nationally covered services, including new screening programmes, IVD tests and prosthetic aids, with resource-neutral revisions to existing coding, nomenclature and prescribing requirements. Together, the measures expand coverage for selected technologies while updating the conditions governing access to existing services.

Italy updated its application process for prioritization under the National HTA Program

On September 22, 2026, the Italian Agency for Regional Healthcare Services (AGENAS) updated the application form and process details for the National HTA Program for Medical Devices (PNHTA-DM) 2026-2028. Applications may be submitted throughout the year by multiple stakeholders, including MedTech companies. Prioritization meetings will be held twice a year: in July, to review submissions received by May 15, and in December, to review submissions received by October 15.

Italy published updated 2026 reimbursement tariffs for outpatient specialist and prosthetic care

On September 21, 2026, the Ministerial Decree updating the maximum national reimbursement tariffs for outpatient specialist services and custom-made prosthetic care provided under the Essential Levels of Care (LEA) came into force. The key changes concern diagnostic procedures, dialysis, rehabilitation, and custom-made prosthetic aids.

Get in touch

Contact us to discuss your needs and learn about our services